ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0308

Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases

Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), autoimmune diseases, interstitial lung disease, pulmonary

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new diagnoses of connective tissue disease (NDC) that present with ILD as the first symptom are not well studied, despite their influence on treatment. The purpose of this study is to investigate the prevalence of NDC in a cohort during their 1st visit to a specific multidisciplinary ILD unit and to describe the clinical, serological, and radiological characteristics of subgroups of patients with final diagnoses of NDC, ILD with autoimmune positivity (ILD-AI), interstitial pneumonia with autoimmune features (IPAF), and non-autoimmune ILD (NA-ILD).

Methods: Retrospective study based on all the first visits referred to a specialized pulmonology ILD clinic (Jan 2021-Oct 2023). 347 medical records were reviewed, with a final sample of 175 (Fig. 1).

Those visits were standardized to optimize the diagnosis of potential CTD associated with ILD. All patients underwent a high-resolution CT and standardized clinical and serological assessments (Fig. 2).

Upon suspicion of NDC, a rheumatological evaluation was conducted using the ACR/EULAR classification criteria for final diagnoses. Descriptive and univariate analyses were performed between the groups (NDC, ILD-AI, IPAF, and NA-ILD) using the Chi-square test/Fisher’s exact test for categorical variables and the ANOVA test for quantitative ones.

Results: The prevalence of NDC and ILD-AI were 9.71% (17/175) and 29.14% (51/175). Primary Sjögren’s syndrome (pSS) was the most common CTD, accounting for 64.7% (11/17), being anti-Ro/anti-La seronegative in 45.5% (5/11) and with histological criteria crucial for diagnosis in 54.4% (6/11). Other diagnosed CTD were rheumatoid arthritis (2/17), systemic sclerosis (1/17), and immune-mediated myopathies (3/17).

Among the 51 ILD-AI cases, the most common serological criterion was ANA≥320 (45.1%, 23/51), and the most prevalent specific autoantibody (aa) anti-PL7 (13.72%, 7/51). Within the ILD-AI group, 29.4% (15/51) met criteria for IPAF, with the most frequent serological criterion being ANA≥320 (53.3%, 8/15), regardless of pattern and specificity, without any predominant aa. Among the ILD-AI group, 3 patients were diagnosed with ANCA-associated ILD (all anti-MPO).

The radiological alternative pattern for Usual Interstitial Pneumonia (UIP) was the most prevalent in the NDC (29.4%) but 23.52% presented with a probable UIP/UIP pattern. The Nonspecific Interstitial Pneumonia (NSIP) pattern was the most prevalent in the IPAF subgroup (60%). (Tab A/B).

Conclusion: pSS was the most frequent CTD initially presenting as ILD, accounting for 64.7% of the NDC cases. Minor salivary gland biopsy enabled diagnosis in more than half of the cases, highlighting its importance, especially in seronegative patients (up to 45.5%) with sicca syndrome.

We consider the concept of ILD-AI to be particularly relevant, as a significant percentage of patients presented with the UIP/probable UIP ILD type, which is not included in the IPAF criteria so they could not be diagnosed despite meeting IPAF serological criteria.

Supporting image 1

Figure 1. Patients selection
a. Sarcoidosis, Langerhans cell histiocytosis, eosinophilic pneumonia, post-infectious organizing pneumonia.
b. This group includes interstitial lung diseases (ILDs) with positive autoimmunity (using the serological criterion os Interstitial Pneumonia with Autoimmune Features IPAF) but that do not meet criteria to establish a definitive connective tissue disease or IPAF in the strict sense.
c. Smoking-related interstitial pneumonia, hypersensitivity pneumonitis, drug toxicity, idiopathic pulmonary fibrosis, unclassified.

Supporting image 2

Figure 2. Routine screening performed to all patients: ANA: antinuclear antibodies; ANCA: Antineutrophil cytoplasmic antibody; CCP: cyclic citrullinated peptide) antibodies

Supporting image 3

A. Characteristics of patients diagnosed with pSS. ANA: antinuclear antibodies; Ro52: anti-Ro52; Ro60; anti-Ro60; usual intersitial pneumonia; non-specific interstitial penumonia.
B. Characteristics of the patients studied. ILD: Interstitial lung disease; CTD: Connective Tissue Diseases; IPAF: interstitial pneumonia with autoimmune features; FVC: predicted forced vital capacity (%); DLco; diffusing capacity of the lungs for carbon monoxide; NINE: non-specific interstitial pneumonia; UIN: usual interstitial pneumonia


Disclosures: J. Meraz-Ostiz: None; A. Puiggròs-Ferrer: None; N. Bou: None; I. Carrión-Barberà: AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Otsuka, 6; J. Monfort: None; C. Pérez-García: None; D. Badenes: None; E. Balcells: None; A. Pros-Simon: None.

To cite this abstract in AMA style:

Meraz-Ostiz J, Puiggròs-Ferrer A, Bou N, Carrión-Barberà I, Monfort J, Pérez-García C, Badenes D, Balcells E, Pros-Simon A. Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/interstitial-lung-disease-as-the-first-clinical-manifestation-of-connective-tissue-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-lung-disease-as-the-first-clinical-manifestation-of-connective-tissue-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology